There is a moment in the life of an invention when the magic trick must become an invoice. For The EVERY Company, that moment arrived somewhere between an omelet at Eleven Madison Park and a purchase order measured in metric tons. The omelet was the better photograph. The purchase order was the better business.
The useful part, quickly
- EVERY uses precision fermentation to make real egg proteins without chickens.
- Its flagship, OvoPro, binds, gels, foams and whips in bakery and prepared-food applications.
- The customer is usually a food manufacturer, not the person eating the cake.
- Roughly $288 million in disclosed equity rounds financed the journey from a $50,000 accelerator cheque to industrial production.
- The model depends on rented manufacturing capacity, repeatable batches and cost-in-use - not novelty alone.
The company began in 2014 as the New Harvest Egg Project. Arturo Elizondo, trained in government rather than biotechnology, met molecular biologist David Anchel through New Harvest's Isha Datar. Anchel had been thinking about how to make egg white without assembling the rest of the bird. In five days, the three built a proposal for IndieBio. The accelerator supplied $50,000 and three months of lab space. The instruction, in effect, was wonderfully blunt: make something and try not to die.
Their proof was a meringue. That choice was clever. Egg white is not merely pale nutrition; its proteins perform a small repertoire of industrial acrobatics. They trap air, set with heat, hold ingredients together and create structure. A meringue makes failure visible. If the protein cannot foam, the dessert slumps into sweet evidence.
The egg was never one thing
EVERY's method borrows a familiar industrial idea. Give a microbe the genetic instructions for a protein, feed it sugar in a fermentation tank, then separate and purify what it makes. The organism is the factory; the stainless-steel vessel is its extremely clean address. The output is not a plant protein pretending to be ovalbumin. It is ovalbumin - the dominant protein in egg white - produced without a hen.
That distinction explains both the product's strength and its awkward fine print. OvoPro behaves like egg protein because it is egg protein. The Vegan Society can certify it because no animal is used or harmed in production. Yet anyone with an egg allergy must still avoid it, and packaged foods must carry an egg-allergen warning. Biology has a dry sense of humor.
The first thing to fail was the easy story
There was no single public explosion, no fermenter flung theatrically across South San Francisco. The early obstacle was more ordinary and more serious: yield. A microorganism can make a protein in a flask and still make it far too expensively for food. Then comes formulation. A purified protein that works in one cookie may sulk in a noodle, a meat analogue or a vat of salad dressing. EVERY's leaders have described the work as pushing microbial yields, testing raw materials and running many small fermentations before trusting a production tank.
The company's public portfolio once ranged brightly across pepsin, a soluble nutrition protein, egg white and a whole liquid egg. Today its website places OvoPro and baking at the center. That is not a confession of scientific defeat. It is the discipline of choosing the product with a clear buyer, a painful supply problem and several measurable jobs to do.
The vegan story opened the door. Volatility kept the meeting going.Why the pitch changed
Food companies have endured avian-flu outbreaks, swinging egg prices, refrigeration costs and cage-free commitments. OvoPro arrives as a powder, can remain shelf-stable for up to 24 months, and is made independently of laying cycles. In 2024, executives said it was already competitive with cage-free egg white on a cost-in-use basis in some applications. That phrase - cost-in-use - matters. If a concentrated protein delivers twice the gelling power, a formulator may need less of it. The price per kilogram is only the beginning of the arithmetic.
Borrow the tanks, own the recipe
The most consequential decision may be the one EVERY did not make. It did not pour hundreds of millions into a wholly owned commercial factory. The company keeps a pilot facility for learning, then transfers the process to contract manufacturers with tanks, operators and downstream equipment already in place. Ingredion provided early commercial reach. AB InBev's BioBrew brought brewing-scale experience. Huvepharma's Biovet subsidiary brought a Bulgarian network with more than nine million liters of installed fermentation capacity.
This is what changed the scale argument. A new fermentation plant can take years to commission. Existing infrastructure can be adapted, provided the process transfers cleanly and purification equipment fits. In June 2026, EVERY said expanded work with Huvepharma would quadruple capacity. It also said annual orders booked in the first four months of 2026 equaled 550 percent of its entire 2025 order volume. Those are company-reported order figures, not audited revenue, but they are the right kind of evidence: customers asking for more of the same thing.
The $55 million Series D announced in November 2025 brought the major disclosed equity rounds to roughly $288 million, depending on how one counts smaller financings. Add a $2 million Defense Department award for a domestic-manufacturing study, and the cost of the journey becomes visible. Precision fermentation may use humble inputs. Making it reliable enough for a national food brand is not a humble undertaking.
The product disappears into other products
EVERY's customers are the people who write ingredient specifications: bakers, product developers, beverage formulators and procurement teams. Unilever's Vegetarian Butcher explored its egg white as a cleaner-label binder in plant-based meat. Grupo Nutresa and Grupo Palacios signed development agreements. Earthbar used OvoBoost in protein lattes. Healthier Comforts put OvoPro into an eight-ounce pouch for home bakers - the first time consumers could buy the ingredient in pantry scale rather than by the industrial bag.
The direct alternatives depend on the job. Conventional dried or liquid egg white remains the incumbent. Aquafaba can foam in a kitchen. Starches and methylcellulose bind industrial foods. Plant-based egg companies formulate around legumes. Other precision-fermentation companies, including Onego Bio, are pursuing ovalbumin too. EVERY's advantage is a decade of process work, commercial partnerships and patent coverage. Its disadvantage is the same molecule that gives it performance: customers seeking an allergen-free binder must look elsewhere.
A playbook worth stealing
The lesson is not “put everything in a fermenter.” That is how one acquires expensive stainless steel and a nervous board. The portable parts are more prosaic:
- Sell the function. “Animal-free” earns attention; binding, shelf life and stable pricing earn a specification.
- Test the difficult use first. A meringue exposed weakness faster than a forgiving recipe would have.
- Rent scale before buying it. Existing operators can turn capital expense into a partnership, if the process is transferable.
- Price the customer's whole system. Inclusion rate, spoilage, refrigeration and supply risk belong in the calculation.
- Prefer repeat orders to spectacular demos. Fine dining proves possibility. Procurement proves a company.
The fine print is made of egg
This approach is a poor fit when the customer needs an allergen-free product, when a recipe depends on yolk fat, color or flavor rather than protein function, or where local regulators have not cleared the ingredient. The contract-manufacturing model also weakens when a process needs unusual equipment, cannot travel between tanks or lacks enough demand to reserve capacity economically.
EVERY's wager is no longer that consumers will wake up longing for precision fermentation. Most people do not wake up longing for baking enzymes either. The wager is that a food company, confronted with another egg-price spike or another disease outbreak, will prefer a powder that performs the same way in January and July. The technology succeeds when the customer stops noticing it. The egg escaped the chicken. Now it is trying to become boring.